Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Citi Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
May 29, 2024 12:57 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $48.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
The analyst comments "Its always tough to draw conclusions from such small data sets (N=4) and ever more so in an open-label, uncontrolled setting, where the... More
